



Call for Grant Applications (CFG) Dermatology-CFG-Atopic Dermatitis AbbVie Independent Education (IE)

Therapeutic Area/Disease State	Dermatology – Atopic Dermatitis
Title	Dermatology-CFG-Atopic Dermatitis
Issue Date:	Monday, May 13, 2024
Due Date/CFG Close Date:	Friday, June 14, 2024

Background

AbbVie is committed to supporting independent, high-quality evidence-based education with the most up-to-date information on current, new, and emerging therapies. This helps to expand knowledge, competence, and performance to improve quality of care for patients and support the elimination of health care disparities in underserved patient populations.

Eligibility Criteria

Grant applicants must be US-based, registered in AbbVie’s Grant Management System at grants.abbvie.com with no outstanding reconciliations and authorized to provide accredited CME/CE by an official accrediting agency (e.g. ACCME, AOA, AAFP, AMA, ADA CERP, ANCC, ACPE, etc.).

Transparency

AbbVie and the AbbVie grant review and approval process complies with applicable laws, regulations, recommendations and guidance, including, without limitation: guidance from the Department of Health & Human Services Office of Inspector General (OIG), Pharmaceutical Research and Manufacturers of America (PhRMA), Advanced Medical Technology Association (AdvaMed), the Accreditation Council for Continuing Medical Education (ACCME), “National Physician Payment Transparency Program: OPEN PAYMENTS” (commonly known as the “Sunshine Act”), and internal AbbVie policies and procedures.

AbbVie, at its sole discretion, may disclose the details of funded independent medical education activities, including as may be required by federal, state, and/or local laws and regulations. This disclosure may include, but shall not be limited to, details of the activity and the grant amount.

Terms and Conditions



AbbVie reserves the right to approve or deny any or all grant applications received as a result of this Call for Grants (CFG) or to cancel, in part or in its entirety, this CFG. AbbVie is not responsible for any costs associated with this CFG submission.

Submission Directions

1. Please go to grants.abbvie.com and sign in. First-time users should click “Register”
2. In the grant application:
 - STEP 1. Select “Submit New Request” to start the submission process.
 - STEP 2. Select the “Education Requests” button to continue the submission process.
 - STEP 3. Read the Request Submission Instructions and click “Proceed” to enter the request form.
 - STEP 4. Enter Request Information on the General Information Tab.
 - In the Activity Sub-Type field, select **Independent Medical Education**
 - **In the Program Title field, start the title of the grant request as: Dermatology-CFG- Atopic Dermatitis**
 - STEP 5. Continue entering requested information as outlined in the grant application, including document uploads.
3. If you have questions or require assistance, please contact:

AbbVie Independent Education Department at 877/228-7177 or via email at abbviegrants@abbvie.com.

IMPORTANT: Grant applications submitted in response to this Call for Grants after the due date will not be reviewed by the AbbVie Independent Education Department and will be automatically declined. In addition, grant applications must include the required information outlined in the Submission Directions. Failure to provide this information may result in the grant application being declined.

Decision Date and Notification

Once AbbVie has reached a decision about the grant application, a system-generated email notification will be sent. If the request is approved, the Authorized Signer identified in the grant application must log into the AbbVie grant management system to review and approve the Letter of Agreement. The Letter of Agreement must be electronically signed by all parties prior to the activity start date. Please do not consider any request approved until an email notification is received from AbbVie stating that the grant request is approved.

Call for Grant Details

Therapeutic Area/Disease state	Dermatology – Atopic Dermatitis
Target Audience	Dermatologists and Dermatology NPs and PAs involved in the care of patients with Atopic Dermatitis
Geographic Scope	United States
Submission Deadline	Friday, June 14, 2024, by 5:00 PM ET
Anticipated Notification Date	No later than mid-July 2024
Budget	\$900,000 Grant requests up to this amount will be considered.
Specific Area of Interest for this CFG	<p>Major Dermatology meetings occurring in late 2024 and early 2025, including but not limited to:</p> <ul style="list-style-type: none"> • 2024 Fall Clinical Dermatology Conference (HIGHEST PRIORITY) • 2025 Winter Clinical Dermatology Conference – Hawaii • Maui Derm Hawaii 2025 • Maui Derm NP+PA Fall 2024 • 2024 SDPA 22nd Annual Fall Dermatology Conference • 2025 ODAC Dermatology, Aesthetic & Surgical Conference • 2025 AAD Annual Meeting <p>Preference will be given to organizations that also include enduring programming as well as innovative educational design approaches that engage and sustain learners’ interest and attention.</p> <p>All proposals should clearly describe the anticipated impact and improvements as a result of the education. Preference will be given to projects that aim to identify the impact of education on real-world clinical behavior.</p> <p>IMPORTANT NOTE: To address the distinct healthcare gaps and educational needs most effectively, AbbVie will not consider submissions that combine multiple disease states within dermatology into a single session/program.</p>

Statement of Need:

With a rapidly evolving landscape in the advanced therapies available for the treatment of moderate-to-severe atopic dermatitis (AD), the following gaps have been identified to enhance HCP education and elevate the standards of treatment:

1. Understanding and application of a treat-to-target framework in AD and the impact of achieving higher and more stringent efficacy targets for itch resolution and skin clearance on patient-reported outcomes, including clinically relevant combinations of these high stringency disease measures.
2. Incorporating into treatment decisions the benefit/risk profile of systemic JAK inhibitors in moderate-to-severe AD, including long-term efficacy, long-term safety, real-world effectiveness, and comparative efficacy of JAK inhibitors and other advanced therapies

The goal is to elevate the standards of treatment and ensure patients are appropriately evaluated and treated to achieve higher levels of skin clearance, optimize patient outcomes, and improve quality of life. Preference will be given to education that addresses emerging evidence on the benefit/risk profile of JAK inhibitors and the impact of high stringency and/or combination of these high stringency treatment targets on patient care in the AD population.

References

1. Czarnowicki T, He H, Krueger JG, Guttman-Yassky E. [Atopic dermatitis endotypes and implications for targeted therapeutics](#). Journal of Allergy and Clinical Immunology. 2019 Jan 1;143(1):1-1.
2. Singh K, Valido K, Swallow M, Okifo KO, Wang A, Cohen JM, Damsky W. [Baseline skin cytokine profiles determined by RNA in situ hybridization correlate with response to dupilumab in patients with eczematous dermatitis](#). Journal of the American Academy of Dermatology. 2023 May 1;88(5):1094-100.
3. Huang IH, Chung WH, Wu PC, Chen CB. [JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis](#): An updated review. Frontiers in immunology. 2022 Dec 8;13:1068260.
4. Silverberg JI, Gooderham M, Katoh N, Aoki V, Pink AE, Binamer Y, Wollenberg A. 327 [Optimizing the management of atopic dermatitis with a new minimal disease activity concept and criteria and consensus-based recommendations for systemic therapy](#). British Journal of Dermatology. 2023 Feb 7;188(Supplement_2):ljac140-022.
5. Silverberg JI et al. [Greater skin clearance and itch improvement in atopic dermatitis are associated with the achievement of stringent patient-reported outcomes: Integrated analysis of three upadacitinib Phase 3 trials](#). Poster Presentation at Maui Derm (2023). J Clin

Aesthet Dermatol. 2023;16(4 Suppl 1):S5–S31.

6. Silverberg JI et al. [The role of itch resolution and skin clearance in patient-reported atopic dermatitis severity and quality of life: real-world insights from TARGET-DERM AD](#). British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, Ijad162.041
7. Silverberg JI, Hong HC, Calimlim BM, Lee WJ, Teixeira HD, Collins EB, Crowell MM, Johnson SJ, Armstrong AW. [Comparative efficacy of targeted systemic therapies for moderate-to-severe atopic dermatitis without topical corticosteroids: an updated network meta-analysis](#). Dermatology and Therapy. 2023 Oct;13(10):2247-64.
8. Silverberg JI, Guttman-Yassky E, Simpson EL, Papp KA, Blauvelt A, Chu CY, Hong HC, Stein Gold LF, Bieber T, Kabashima K, Rosmarin D. [502-Efficacy and safety of upadacitinib through 140 weeks in adolescents and adults with moderate-to-severe atopic dermatitis: phase 3 randomized clinical trial results](#). British Journal of Dermatology. 2024 Feb;190(Supplement_2):ii8-.
9. Bunick C, Chovatiya R, Guttman E, Shahriari M, Boguniewicz M, Gao X, Greiwe J, Blauvelt A, Schuttelaar ML, Irvine AD, Levy GF. [533-Long-term 5-year safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis including over 7000 patient-years of exposure](#). British Journal of Dermatology. 2024 Feb;190(Supplement_2):ii35-6.
10. Ingrassia JP, Maqsood MH, Gelfand JM, et al. [Cardiovascular and Venous Thromboembolic Risk With JAK Inhibitors in Immune-Mediated Inflammatory Skin Diseases: A Systematic Review and Meta-Analysis](#). JAMA Dermatol. 2024;160(1):28-36. doi:10.1001/jamadermatol.2023.4090
11. Burmester GR, Cohen SB, Winthrop KL, Nash P, Irvine AD, Deodhar A, Mysler E, Tanaka Y, Liu J, Lacerda AP, Palac H. [Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis](#). RMD open. 2023 Feb 1;9(1):e002735.
12. Daniele S, Bunick C. [JAK Inhibitor Safety Compared to Traditional Systemic Immunosuppressive Therapies](#). Journal of Drugs in Dermatology: JDD. 2022 Dec 1;21(12):1298-303.
13. HCP Live. Upadacitinib Superior in Efficacy to Dupilumab for Atopic Dermatitis in Head-to-Head Study. April 25, 2024. <https://www.hcplive.com/view/upadacitinib-superior-in-efficacy-to-dupilumab-for-atopic-dermatitis-in-head-to-head-study>